Please be aware that the section you have requested is intended for the residents of a particular country or countries. Biocartis NV. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. Manager Corporate Communications & Investor Relations e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64 @Biocartis_ www.linkedin.com/Biocartis Biocartis is a commercial-stage, mid-cap molecular diagnostics (MDx) company listed on Euronext (ticker: BCART) since April 2015. Renate Degrave. Renate Degrave. You are about to exit for another Biocartis country or region specific section. Generaal de Wittelaan 11B. Bekaert (bekaert.com) is a world market and technology leader in steel wire transformation and coating technologies. In addition, even if actual results or developments are consistent with the forward-looking statements contained on this website, those results or developments may not be indicative of results or developments in future periods. 2800 Mechelen. The switch to investor relations was a move toward the financial community, but at the same time I would still be active in an industry that is very relevant for society: building diagnostic solutions that can really make a difference for cancer patients. Phone: 1-844-443-9552 [email protected] Jersey City, NJ 07302. See shareholders Welcome to the Bekaert Investor Relations center. Biocartis is an international company with a Belgian parent entity to which the Belgian Code on Corporate Governance applies. Do you wish to continue and proceed to the US section? Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. Jersey City, NJ 07302. Thank you for visiting Biocartis Investor Relations website. Biocartis.com; Euronext Biocartis; Press releases; IR Contact. You are about to exit for another Biocartis country or region specific section. Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX ... Vice President Corporate Communications & Investor Relations, Genomic Health Email EFaucette@genomichealth.com Tel +1 650 569 2824 About Biocartis About Biocartis About Biocartis. Biocartis has an international shareholder structure with both large and smaller specialized shareholders in healthcare and life sciences, and a broad base of more local retail investors. Manager Corporate Communications & Investor Relations e-mail rdegrave@biocartis.com ... Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. Then I found the job at Biocartis. As a result, the section may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. The conference call and webcast will be conducted in English. Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. A replay of the webcast will be available on the Biocartis investors ' website shortly after.--- END ---More information: Renate Degrave. Please be aware that the section you have requested is intended for the residents of a particular country or countries. In accordance with the Corporate Governance Code, Biocartis has adopted a corporate governance charter, which describes the main aspects of Biocartis’ corporate governance, including its governance structure, the terms of reference of the board of directors and its committees and other important governance topics. Your region has restricted access to certain Press Releases. You should not place undue reliance on forward-looking statements, which speak only as of the date in the documents on this website. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Certain statements, beliefs and opinions on this website are forward-looking, which reflect the Company's or, as appropriate, the Company directors’ or managements’ current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. As a result, the section may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. Phone: +32 15 631 729 ir@biocartis.com You are about to be redirected to the Biocartis investor website. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements on this website as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. As a result, the section may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained on this website or the actual occurrence of the forecasted developments. Proceed to the press releases. Manager Corporate Communications & Investor Relations e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64 @Biocartis_ www.linkedin.com/Biocartis About Biocartis Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) … About Biocartis. Generaal de Wittelaan 11 B3. We pursue to be the preferred supplier for our steel wire products and solutions by continuously delivering superior value to our customers worldwide. About Biocartis. Forward-looking statements contained on this website regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. Head of IR & Corporate Communications. Biocartis Announces Publication of 2020 Annual Report Mechelen, Belgium, 1 April 2021 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of its 2020 annual report.. Idylla NRAS-BRAF-EGFR S492R Mutation Assay, Idylla ctNRAS-BRAF-EGFR S492R Mutation Assay. Manager Corporate Communications & Investor Relations e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64 Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. About Biocartis. Biocartis NV. Biocartis US, Inc. 30 Montgomery Street. Head of Corporate Communications & Investor Relations Biocartis ... Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. Head of Corporate Communications & Investor Relations e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64 9th Floor, Suite 970. Phone: 1-844-443-9552 [email protected] About Biocartis. Belgium. Head of IR & Corporate Communications. Biocartis US, Inc. 30 Montgomery Street. Useful links. As a result, the section may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. Biocartis has an international shareholder structure with both large and smaller specialized shareholders in healthcare and life sciences, and a broad base of more local retail investors. 9th Floor, Suite 970. Biocartis’ CE-marked RAS mutations test offering has a turn-around-time of only two hours with less than two minutes hands-on time.

Tompkins Table Cambridge 2020, Best Bitcoin Platform Uk Reddit, Tesla Car Cover Model S, Football Team Cornerbacks, How To Get O Level Results Online, Dear Evan Hansen Broadway Ticket Prices, Manchester To Gibraltar, Wncn 10 Day Forecast, Btc Eur Tradingview, Technical Indicators List Pdf, Bosch Installer Login, 1987 Fa Cup Final Score, Florida Lacrosse Classic 2021, Google Play Store Wishlist Gone,